Source comparison
Head-to-Head vs. Cross-Trial: Why There Is No Fair Comparison
Here is the single most important methodological point in this article, and it deserves its own heading: AOD-9604 and tesamorelin have never been compared in the same trial. There is no randomized head-to-head study, no shared control group, no common endpoint
This comparison does not assign a generated winner or score.
- Here is the single most important methodological point in this article, and it deserves its own heading: AOD-9604 and tesamorelin have never been compared in the same trial. There is no randomized head-to-head study, no shared control group, no common endpoint, and no common population. Every “which is better for fat loss” claim you will read is therefore a cross-trial inference — taking a number from one study and setting it beside a number from a completely different study, run in a different population, with a different endpoint, by a different route.
- Cross-trial comparisons are fragile even when both sides have good data. In this case the two sides are not even the same category of evidence: tesamorelin’s figures come from published Phase 3 RCTs in HIV-lipodystrophy patients measuring CT-quantified visceral fat;[1][2] AOD-9604’s figures come from an unpublished Phase 2b obesity trial that failed, plus preclinical work.[8] Put bluntly: you cannot fairly “compare” a confirmed positive with an unconfirmed negative and declare a winner on effect size. The honest comparison is about evidence tier, not about which percentage is larger.
- AOD-9604 vs tesamorelin, directly
- No shared trial, no common endpoint or population
- None (no direct data)
- Not established; any ranking is inference, not measurement
- Tesamorelin for visceral fat
- Two Phase 3 RCTs (n=806; n=404), CT-measured VAT[1][2]
- Strong (direct, confirmatory)
- Real effect — but only in HIV-associated lipodystrophy
- AOD-9604 for weight loss
- Failed 24-week Phase 2b (unpublished) + animal/in-vitro[8]
- Weak / negative
- Not demonstrated in humans
- AOD-9604 for joints/cartilage
- Animal model (rabbit osteoarthritis, intra-articular)[7]
- Animal only
- Preclinical; not a human fat-loss claim at all